What is ABSI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.74B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABSI?

P/E (TTM) is n/a and 52-week range is $2.24 to $12.05 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABSI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABSI?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-12.97B, EPS (TTM) near $-0.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Absci Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vancouver Washington, Washington, US, 168.8M shares outstanding, ISIN US00091E1091 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Absci Corp

$ABSI

Health Care · Biotechnology

IR Run Scenarios

$10.16

+13.65%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 140 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Employees

140

Website

www.absci.com/

IPO

2021-07-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)